neosynephrine 1% phenylephrine hydrochloride 10mg/1ml injection usp ampoule
pfizer australia pty ltd - phenylephrine hydrochloride, quantity: 10 mg/ml - injection, solution - excipient ingredients: water for injections; sodium citrate dihydrate; sodium metabisulfite; nitrogen; sodium chloride; citric acid - indications as at 01 jan 1991 : phenylephrine hydrochloride is intended for the maintenance of an adequate level of blood pressure during spinal and inhalation anesthesia and for the treatment of vascular failure in shock, shock-like states, and drug-induced hypotension, of hypersensitivity. it is also employed to overcome paroxysmal supraventricular tachycardia, to prolong spinal anesthesia, and as a vasoconstrictor in regional analgesia.
minidiab
pfizer australia pty ltd - glipizide, quantity: 5 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; maize starch; lactose monohydrate; stearic acid - minidiab is indicated as an adjunct to diet and exercise for the control of hyperglycaemia and its associated symptomatology in patients with non-insulin-dependent diabetes mellitus (niddm; type ii), formerly known as maturity-onset diabetes, after an adequate trial of dietary therapy has proved unsatisfactory. in initiating treatment for non-insulin-dependent diabetes, diet should be emphasised as the primary form of treatment. caloric restriction and weight loss are essential in the obese diabetic patient. proper dietary management alone may be effective in controlling the blood glucose and symptoms of hyperglycaemia. the importance of regular physical activity should also be stressed, and cardiovascular risk factors should be identified and corrective measures taken where possible. if this treatment program fails to reduce symptoms and/or blood glucose the use of an oral sulphonylurea or insulin should be considered. use of minidiab must be viewed by both the physician and patient as a treatment in additio
levophed 1:1000 2mg/2ml injection ampoule
pfizer australia pty ltd - noradrenaline (norepinephrine) acid tartrate monohydrate -
colestid colestipol hydrochloride 5g granules sachets
pfizer australia pty ltd - colestipol hydrochloride -
strong potassium chloride solution 1g/4ml injection
pfizer australia pty ltd - potassium chloride -
strong potassium chloride solution b.p. 1.5g in 10ml
pfizer australia pty ltd - potassium chloride -
potassium chloride solution 1.0g in 10ml
pfizer australia pty ltd - potassium chloride -
sinequan 25mg capsule
pfizer australia pty ltd - doxepin hydrochloride -
ibrance palbociclib 100 mg capsule blister pack
pfizer australia pty ltd - palbociclib, quantity: 100 mg - capsule, hard - excipient ingredients: magnesium stearate; iron oxide yellow; silicon dioxide; iron oxide red; microcrystalline cellulose; sodium starch glycollate type a; lactose monohydrate; titanium dioxide; gelatin; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; simethicone; ethanol; shellac; sulfuric acid - ibrance is indicated for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer in combination with: ? an aromatase inhibitor as initial endocrine-based therapy ? fulvestrant in patients who have received prior therapy.
ibrance palbociclib 75 mg capsule blister pack
pfizer australia pty ltd - palbociclib, quantity: 75 mg - capsule, hard - excipient ingredients: silicon dioxide; iron oxide yellow; iron oxide red; titanium dioxide; magnesium stearate; sodium starch glycollate type a; gelatin; lactose monohydrate; microcrystalline cellulose; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; simethicone; ethanol; shellac; sulfuric acid - ibrance is indicated for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer in combination with: ? an aromatase inhibitor as initial endocrine-based therapy ? fulvestrant in patients who have received prior therapy.